Industry
Biotechnology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 2:28 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:19 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 12:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:28 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 6:34 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 5:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 2:22 pm
Portfolio Pulse from Avi Kapoor
August 01, 2024 | 2:15 pm
Portfolio Pulse from Vandana Singh
August 01, 2024 | 1:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.